Product image of Magnesium I.V. Verla (Magnesium Sulfate Heptahydrate) supplied by GNH India

Magnesium I.V. Verla

Active Ingredient:
Magnesium Sulfate Heptahydrate
Origin:
EU

Magnesium I.V. Verla (Magnesium Sulfate Heptahydrate)

Magnesium sulfate, the active ingredient in Magnesium I.V. Verla, is a magnesium salt / electrolyte presented as an intravenous solution for intravenous use. It is employed to correct magnesium deficiency, prevent and treat eclampsia or preeclampsia, manage certain cardiac arrhythmias such as torsades de pointes, and serve as an adjunct in severe asthma exacerbations.

GNH India supplies Magnesium I.V. Verla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide, ensuring consistent quality and regulatory compliance.

Manufacturer / TM Owner

Verla-Pharm Arzneimittel Gmbh & Co. Kg

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Magnesium I.V. Verla provides magnesium ions to address electrolyte disturbances and related clinical conditions.
  • Magnesium deficiency: restores normal serum magnesium levels and supports enzymatic functions.
  • Eclampsia / preeclampsia: prevents seizures and stabilizes blood pressure in pregnant patients at risk.
  • Torsades de pointes and other cardiac arrhythmias: helps terminate ventricular tachyarrhythmias by antagonizing calcium influx.
  • Severe asthma exacerbations: acts as a bronchodilator adjunct to improve airway smooth‑muscle relaxation.

How It Works

  • Magnesium sulfate dissociates to release Mg2+ ions that serve as essential cofactors for over 300 enzymatic reactions, stabilize ATP, and modulate ion channels. The ions competitively inhibit calcium entry through voltage‑gated channels, reduce neuronal excitability, and promote smooth‑muscle relaxation, thereby correcting electrolyte deficits and attenuating hyper‑excitability in cardiac and respiratory tissues.

Side Effects

Magnesium I.V. Verla may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Flushing or feeling of warmth: transient sensation during infusion.
  • Nausea: mild gastrointestinal upset.
  • Hypotension: drop in blood pressure, especially with rapid administration.

Serious or Rare Side Effects

  • Hypermagnesemia: elevated serum magnesium causing muscle weakness or cardiac effects.
  • Cardiac arrest: severe conduction disturbances leading to loss of cardiac output.
  • Respiratory depression: reduced respiratory drive in high concentrations.

Precautions & Warnings

  • When using Magnesium I.V. Verla, clinicians should consider several safety measures.
  • Renal impairment: monitor serum magnesium and adjust infusion rate.
  • Cardiac disease: observe for bradycardia or heart block.
  • Neuromuscular disorders: use cautiously due to risk of muscle weakness.
  • Pregnancy: administer only when benefit outweighs potential risk to fetus.
  • Concomitant medications: review drugs that affect magnesium levels.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Magnesium I.V. Verla can interact with other medicines, requiring careful assessment.

Major Interactions (Avoid)

  • Calcium channel blockers: additive hypotensive effect.
  • Neuromuscular blocking agents: potentiation of muscle relaxation.
  • Other magnesium‑containing products: risk of hypermagnesemia.

Moderate Interactions (Monitor Closely)

  • Loop diuretics: increase renal magnesium loss, may require dose adjustment.
  • ACE inhibitors or ARBs: alter renal handling of magnesium, monitor levels.

Frequently Asked Questions

Magnesium I.V. Verla is an intravenous magnesium sulfate solution used to correct magnesium deficiency, prevent and treat eclampsia or preeclampsia in pregnancy, manage certain cardiac arrhythmias such as torsades de pointes, and act as an adjunct therapy in severe asthma attacks.

Magnesium sulfate releases Mg2+ ions that act as cofactors for many enzymatic processes, stabilize cell membranes, and antagonize calcium-mediated excitability. This helps normalize electrolyte balance, relax smooth muscle, and reduce neuronal and cardiac hyper‑excitability.

The appropriate dose of Magnesium I.V. Verla is determined by the prescribing clinician based on the patient’s clinical condition, serum magnesium level, renal function, and the specific indication being treated. No fixed regimen is provided here.

Magnesium I.V. Verla may be used in pregnancy when the expected benefit justifies any potential risk to the fetus, such as in the management of eclampsia. Safety during breastfeeding has not been fully established, so clinical judgment is required.

To order Magnesium I.V. Verla, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Magnesium I.V. Verla is a sterile intravenous formulation of magnesium sulfate, offering rapid systemic delivery compared with oral or topical magnesium salts. It provides precise dosing control for acute settings, whereas oral preparations are generally used for chronic supplementation.

Magnesium I.V. Verla should be stored at 2‑8 °C, protected from light, and kept in its original container. It must not be frozen or shaken vigorously. Before use, inspect the solution for particulate matter or discoloration.

The product is administered intravenously by a qualified healthcare professional. It is typically infused slowly under continuous monitoring of vital signs and serum magnesium levels, with the infusion rate adjusted according to the patient’s response and clinical protocol.

Serious risks include hypermagnesemia, which can cause muscle weakness, cardiac arrest, or respiratory depression. Rapid infusion may also lead to severe hypotension. Prompt recognition and monitoring are essential to mitigate these potentially life‑threatening events.

Patients with severe renal impairment, existing hypermagnesemia, uncontrolled heart block, or known hypersensitivity to magnesium sulfate should not receive Magnesium I.V. Verla. Clinicians must evaluate each individual’s medical history before administration.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Magnesium Sulfate Heptahydrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT